W W Leitner

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc DNA and RNA-based vaccines: principles, progress and prospects
    W W Leitner
    National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892 1502, USA
    Vaccine 18:765-77. 1999
  2. pmc Type I Interferons are essential for the efficacy of replicase-based DNA vaccines
    Wolfgang W Leitner
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:5110-8. 2006
  3. pmc Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines
    Wolfgang W Leitner
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42 Bethesda, MD 20892 1502, USA
    Vaccine 22:1537-44. 2004
  4. pmc Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy
    Wolfgang W Leitner
    Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Malar J 9:145. 2010
  5. pmc Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
    Wolfgang W Leitner
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 9:33-9. 2003
  6. pmc Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
    W W Leitner
    National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 60:51-5. 2000
  7. ncbi request reprint Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants
    W W Leitner
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Pharm Des 7:1641-67. 2001
  8. pmc Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen
    C E Touloukian
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892
    Cancer Res 61:8100-4. 2001
  9. ncbi request reprint The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis
    S Frank
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Behesda, Maryland 20892, USA
    Dev Cell 1:515-25. 2001
  10. pmc Assumptions of the tumor 'escape' hypothesis
    Nicholas P Restifo
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Cancer Biol 12:81-6. 2002

Collaborators

Detail Information

Publications25

  1. pmc DNA and RNA-based vaccines: principles, progress and prospects
    W W Leitner
    National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892 1502, USA
    Vaccine 18:765-77. 1999
    ..Thus, the enhanced immunogenicity of 'self-replicating' genetic vaccines may be a result of the production of pro-inflammatory dsRNA, which mimics an RNA-virus infection of host cells...
  2. pmc Type I Interferons are essential for the efficacy of replicase-based DNA vaccines
    Wolfgang W Leitner
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:5110-8. 2006
    ..These results suggest a central role for Type I IFNs in the mechanism of replicase-based DNA vaccines and indicate that vaccines can be enhanced by enabling their capacity to triggering innate anti-viral defense pathways...
  3. pmc Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines
    Wolfgang W Leitner
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42 Bethesda, MD 20892 1502, USA
    Vaccine 22:1537-44. 2004
    ..Our findings also provide an explanation for the paradoxical observation that replicase-based DNA vaccines are much more immunogenic than conventional constructs despite reduced antigen production...
  4. pmc Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy
    Wolfgang W Leitner
    Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Malar J 9:145. 2010
    ..Finding shortcomings of both approaches, an alternative approach was explored, i.e., the subcutaneous challenge...
  5. pmc Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
    Wolfgang W Leitner
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 9:33-9. 2003
    ....
  6. pmc Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
    W W Leitner
    National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 60:51-5. 2000
    ..Because of their safety and efficacy, plasmid DNA replicons may be useful in the development of recombinant vaccines for infectious diseases and cancer...
  7. ncbi request reprint Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants
    W W Leitner
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Pharm Des 7:1641-67. 2001
    ..Despite highly promising results in many animal tumor models the efficacy of nucleic acid vaccines and adjuvants in the clinic remains to be seen...
  8. pmc Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen
    C E Touloukian
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892
    Cancer Res 61:8100-4. 2001
    ..polypeptide-specific CD8+ T cells capable of recognizing P.polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P.polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines...
  9. ncbi request reprint The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis
    S Frank
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Behesda, Maryland 20892, USA
    Dev Cell 1:515-25. 2001
    ..Remarkably, inhibition of Drp1 blocks cell death, implicating mitochondrial fission as an important step in apoptosis...
  10. pmc Assumptions of the tumor 'escape' hypothesis
    Nicholas P Restifo
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Cancer Biol 12:81-6. 2002
    ..The dysregulation characteristic of the transformed genome is also what makes tumor immunity, a specialized form of autoimmunity, possible...
  11. pmc Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function
    Christopher E Touloukian
    National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA
    Cancer Res 62:5144-7. 2002
    ..These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes...
  12. pmc Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1
    Christopher E Touloukian
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:1579-85. 2003
    ..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags...
  13. ncbi request reprint Replicase-based DNA vaccines for allergy treatment
    Sandra Scheiblhofer
    Department of Molecular Biology, University of Salzburg, Salzburg, Austria
    Methods Mol Med 127:221-35. 2006
    ....
  14. ncbi request reprint Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization
    Maximilian Gabler
    Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg, Austria
    J Allergy Clin Immunol 118:734-41. 2006
    ..Both aspects are important requirements for efficient and safe DNA-based immunotherapy of type I allergies...
  15. ncbi request reprint Inhibitory effects of B cells on antitumor immunity
    Satoshi Inoue
    Center for Biologics Evaluation and Research, Division of Hematology, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    Cancer Res 66:7741-7. 2006
    ..Our studies provide the first mechanistic basis for the concept that B-cell depletion could therapeutically enhance antitumor immune responses to certain tumors by decreasing IL-10 production from B cells...
  16. ncbi request reprint Complement 3d: from molecular adjuvant to target of immune escape mechanisms
    Elke S Bergmann-Leitner
    Department of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Room 3W76, Silver Spring, MD 20910, USA
    Clin Immunol 121:177-85. 2006
    ....
  17. ncbi request reprint Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A
    Douglas S Walsh
    Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
    Vaccine 24:4167-78. 2006
    ..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A...
  18. ncbi request reprint Is genetic vaccination against allergy possible?
    Richard Weiss
    Department of Molecular Biology, Division of Allergy and Immunology, University of Salzburg, Salzburg, Austria
    Int Arch Allergy Immunol 139:332-45. 2006
    ....
  19. ncbi request reprint Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native protein
    Adela R Cardones
    Dermatology, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 12N258, Bethesda, MD 20892, USA
    Microvasc Res 71:32-9. 2006
    ..In summary, gene gun-assisted delivery of cDNA encoding LYVE-1 into skin resulted in reliable production of antisera that specifically and functionally recognized native LYVE-1 protein...
  20. ncbi request reprint Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases
    Richard Weiss
    Department of Molecular Biology, University of Salzburg, A 5020 Salzburg, Austria
    Curr Drug Targets Inflamm Allergy 4:585-97. 2005
    ..Finally, the development of DNA multi vaccines and fusion vaccines for protective and therapeutic applications against certain groups of allergens is addressed...
  21. ncbi request reprint Danger, death and DNA vaccines
    Elke S Bergmann-Leitner
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Microbes Infect 6:319-27. 2004
    ..Among the countless approaches to improve them is the stimulation of the innate immune system by promoting the apoptotic death of the transfected host cells, which is the focus of this review...
  22. pmc DNA vaccines and apoptosis: to kill or not to kill?
    Wolfgang W Leitner
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Invest 112:22-4. 2003
  23. ncbi request reprint DNA vaccines for non-infectious diseases: new treatments for tumour and allergy
    Wolfgang W Leitner
    Immunology Group, Institute of Chemistry and Biochemistry, University of Salzburg, Salzburg, Austria
    Expert Opin Biol Ther 3:627-38. 2003
    ..These strategies, individually or in combination, hold the potential of making DNA vaccines useful for application in the clinic...
  24. ncbi request reprint Myth, menace or medical blessing? The clinical potential and problems of genetic vaccines
    Wolfgang W Leitner
    Expert Opin Biol Ther 3:1-4. 2003
  25. ncbi request reprint Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy?
    Elke S Bergmann-Leitner
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Curr Pharm Des 9:2009-23. 2003
    ..Any tumor therapy puts selective pressure on tumors thus favoring the outgrowth of therapy-resistant variants. This review summarizes current knowledge on tumor escape mechanisms and some of the efforts to overcome these mechanisms...